fda-approved compounding pharmacy semaglutide Compounded Novo asks FDA to prevent

[DOI] [PubMed] [Google Scholar] 113.Yadav A., Kataria M.A., Saini V., Yadav A

In research it is used in models of obesity and metabolic syndrome

Orem, UT June 9, 2026 DietsMD.com, an online medical weight loss platform specializing in doctor-guided GLP-1 treatment programs, today announced the expansion of its telehealth weight loss services designed to help eligible patients explore semaglutide, tirzepatide, and emerging oral GLP-1 treatment options through a streamlined online experience

Many have Canada in their name but get their drugs elsewhere

Looking to the future of what this means for GLP-1 deal making, the central message is that obesity is still very much a hot bed as there is need to invest in emerging modalities that can be combined/co-administered with GLP-1s and mitigate risks/target the residual unmet need associated with GLP-1s including the serious side effects such as nausea, vomiting, weight regain and excessive muscle loss

While protein stimulates GLP-1 production (beneficial), certain amino acid patterns may also affect DPP-4 expression